These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 7840053)
61. [Hemodynamic and clinical effects and treatment tolerance with low-dose iv amrinone in patients with refractory heart failure: a multicenter study. The Group for Research on Amrinone in the Treatment of Refractory Heart Failure]. Dei Cas L; Metra M; Nodari S; Raddino R; Visioli O Cardiologia; 1991 May; 36(5):363-71. PubMed ID: 1756541 [TBL] [Abstract][Full Text] [Related]
62. Long-term follow-up after conversion from intravenous epoprostenol to oral therapy with bosentan or sildenafil in 13 patients with pulmonary arterial hypertension. Johnson RF; Loyd JE; Mullican AL; Fink CA; Robbins IM J Heart Lung Transplant; 2007 Apr; 26(4):363-9. PubMed ID: 17403478 [TBL] [Abstract][Full Text] [Related]
64. Rapid and high-dose titration of epoprostenol improves pulmonary hemodynamics and clinical outcomes in patients with idiopathic and heritable pulmonary arterial hypertension. Tokunaga N; Ogawa A; Ito H; Matsubara H J Cardiol; 2016 Dec; 68(6):542-547. PubMed ID: 27005767 [TBL] [Abstract][Full Text] [Related]
65. Hemodynamics as surrogate end points for survival in advanced heart failure: an analysis from FIRST. Shah MR; Stinnett SS; McNulty SE; Gheorghiade M; Zannad F; Uretsky B; Adams KF; Califf RM; O'connor CM Am Heart J; 2001 Jun; 141(6):908-14. PubMed ID: 11376303 [TBL] [Abstract][Full Text] [Related]
66. Dobutamine effects on spontaneous variability of ventricular arrhythmias in patients with severe chronic heart failure: the Italian Multicenter Study. Puddu PE; Papalia U; Schiariti M; Usta C; Ital Heart J; 2004 Sep; 5(9):693-701. PubMed ID: 15568599 [TBL] [Abstract][Full Text] [Related]
67. Early and medium term results of tailored therapy for heart failure. Martins S; Soares RM; do Rosário L; Quininha J; Antunes AM Rev Port Cardiol; 2001 Mar; 20(3):261-82. PubMed ID: 11417309 [TBL] [Abstract][Full Text] [Related]
68. A multicenter study of the safety and efficacy of benazepril hydrochloride, a long-acting angiotensin-converting enzyme inhibitor, in patients with chronic congestive heart failure. Insel J; Mirvis DM; Boland MJ; Cinquegrani MP; Shanes J; Rubin SA; Whalen JJ Clin Pharmacol Ther; 1989 Mar; 45(3):312-20. PubMed ID: 2537699 [TBL] [Abstract][Full Text] [Related]
69. Short-term intravenous milrinone for severe congestive heart failure: the good, bad, and not so good. Varriale P; Ramaprasad S Pharmacotherapy; 1997; 17(2):371-4. PubMed ID: 9085331 [TBL] [Abstract][Full Text] [Related]
70. [Acute changes in the hemodynamic profile and circulating levels of atrial natriuretic peptide induced by dobutamine in severe heart failure]. La Vecchia L; Bottero M; Centofante P; Bedogni F; Ometto R; Cera A; Fortunato A G Ital Cardiol; 1996 Aug; 26(8):863-74. PubMed ID: 9005168 [TBL] [Abstract][Full Text] [Related]
71. Aerosolized prostacyclin and iloprost in severe pulmonary hypertension. Olschewski H; Walmrath D; Schermuly R; Ghofrani A; Grimminger F; Seeger W Ann Intern Med; 1996 May; 124(9):820-4. PubMed ID: 8610951 [TBL] [Abstract][Full Text] [Related]
72. Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): A study of 15 patients with moderate to severe portopulmonary hypertension. Krowka MJ; Frantz RP; McGoon MD; Severson C; Plevak DJ; Wiesner RH Hepatology; 1999 Sep; 30(3):641-8. PubMed ID: 10462369 [TBL] [Abstract][Full Text] [Related]
73. Is there a role for epoprostenol in the management of heart failure? Haywood GA; Adams KF; Gheorghiade M; McKenna WJ Am J Cardiol; 1995 Jan; 75(3):44A-50A. PubMed ID: 7840054 [TBL] [Abstract][Full Text] [Related]
74. Safety and hemodynamic effects of intravenous triiodothyronine in advanced congestive heart failure. Hamilton MA; Stevenson LW; Fonarow GC; Steimle A; Goldhaber JI; Child JS; Chopra IJ; Moriguchi JD; Hage A Am J Cardiol; 1998 Feb; 81(4):443-7. PubMed ID: 9485134 [TBL] [Abstract][Full Text] [Related]
75. Intermittent, ambulatory dobutamine infusions in patients with severe congestive heart failure. Krell MJ; Kline EM; Bates ER; Hodgson JM; Dilworth LR; Laufer N; Vogel RA; Pitt B Am Heart J; 1986 Oct; 112(4):787-91. PubMed ID: 3766379 [TBL] [Abstract][Full Text] [Related]
76. Role of prostacyclin in the treatment of primary pulmonary hypertension. Cremona G; Higenbottam T Am J Cardiol; 1995 Jan; 75(3):67A-71A. PubMed ID: 7840058 [TBL] [Abstract][Full Text] [Related]
77. The effects of epoprostenol on drug disposition. I: A pilot study of the pharmacokinetics of digoxin with and without epoprostenol in patients with congestive heart failure. Carlton LD; Patterson JH; Mattson CN; Schmith VD J Clin Pharmacol; 1996 Mar; 36(3):247-56. PubMed ID: 8690819 [TBL] [Abstract][Full Text] [Related]
79. Arrhythmic effects of intermittent dobutamine therapy in chronic heart disease failure. The Working Group of Cardiology of the Academic Committee of Veszprém, Hungary. Tarján J; Nagy L; Liziczai I; Junger E Am J Ther; 1998 Nov; 5(6):405-11. PubMed ID: 10099085 [TBL] [Abstract][Full Text] [Related]
80. Effects of Acute GLP-1 Infusion on Pulmonary and Systemic Hemodynamics in Patients With Heart Failure: A Pilot Study. Clarke SJ; Pettit S; Giblett JP; Zhao T; Kydd AC; Albrechtsen NJW; Deacon CF; Parameshwar J; Hoole SP Clin Ther; 2019 Jan; 41(1):118-127.e0. PubMed ID: 30598343 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]